Prot #TL-895-203: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with KRT-232 in Subjects with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)

Project: Research project

Project Details

StatusActive
Effective start/end date5/4/215/4/24

Funding

  • PSI Pharma Support America Inc. (Prot #TL-895-203)
  • Telios Pharma, Inc. (Prot #TL-895-203)